The Hong Kong Life Sciences team represented TransThera Biosciences on its exclusive license agreement with LG Chem Life Sciences, pursuant to which TransThera granted to LG Chem an exclusive license for the development and commercialization of TransThera’s TT-01025. Under the terms of the agreement, LG Chem obtained exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025. TransThera will receive upfront payment as well as development and sales milestone payments, totaling up to $350 million, plus tiered royalties on the annual net sales. LG Chem will be responsible for the further development, manufacturing and commercialization of TT-01025.
TT-01025 is a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive AmineOxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promisingefficacy in pre-clinical investigationinnon-alcoholic steatohepatitis (NASH). TT-01025 is expected to enter Phase I trial in early 2021 in the U.S.
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases.
For additional details on the agreement, please read the press release.